Drug name - Reyvow

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Apr, 2025

(2 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(15 years from now)

CN100352817C ELI LILLY AND CO As
Mar, 2023

(5 months from now)

CN1642939A ELI LILLY AND CO As
Mar, 2023

(5 months from now)

IN238831B ELI LILLY AND CO A Substituted Pyridinoylipieridines Compound As 5-Ht If Agonists
Mar, 2023

(5 months from now)

IN200401392P2 ELI LILLY AND CO Pyridinoylpiperidines As 5-Ht1F Agonists
Mar, 2023

(5 months from now)

EP1492786B1 ELI LILLY AND CO Pyridinoylpiperidines As 5-Ht1F Agonists
Mar, 2023

(5 months from now)

EP1492786A1 ELI LILLY AND CO Pyridinoylpiperidines As 5-Ht1F Agonists
Mar, 2023

(5 months from now)

EP3551617A1 ELI LILLY AND CO Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists
Dec, 2037

(15 years from now)

EP3551617B1 ELI LILLY AND CO Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists
Dec, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists Mar, 2023

(5 months from now)

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.